Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease.
Acetylcholinesterase inhibitors (AChIs) have been demonstrated to improve Alzheimer disease symptoms. Whether the use of AChIs varies by ethnicity is unknown. More than 2500 ethnically diverse patients (6% African American, 14% Latino, and 7% Asian patients) from the Alzheimer's Disease Research Centers in California were studied. Compared with white patients with AD, minority patients had 40% lower odds of AChI use (odds ratio 0.6, 95% confidence interval: 0.5 to 0.7).
Mehta
Kala M
KM
Division of Geriatrics, Department of Medicine, University of California, San Francisco, CA, USA. kala@itsa.ucsf.edu
Yin
Maggie
M
Resendez
Cynthia
C
Yaffe
Kristine
K
D000109:Acetylcholine / Q000378:metabolism; D000110:Acetylcholinesterase / Q000378:metabolism; D001741:Black or African American / Q000235:genetics; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000208:ethnology* / Q000235:genetics; D044466:Asian People / Q000235:genetics; D001921:Brain / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology; D001923:Brain Chemistry / Q000235:genetics*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006630:Hispanic or Latino / Q000235:genetics; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D044465:White People / Q000235:genetics
D002800:Cholinesterase Inhibitors; D000110:Acetylcholinesterase; D000109:Acetylcholine